Ultomiris approved in the EU for children and adolescents with paroxysmal nocturnal haemoglobinuria
03 September 2021 07:00 BST Ultomiris approved in the EU for children and adolescents with paroxysmal nocturnal haemoglobinuria Approval based on interim results from Phase III trial demonstrating complete terminal complement inhibition with reduced dosing frequency compared to Soliris Ultomiris (ravulizumab) has been approved in the European Union for expanded use to include children (with a body weight of 10 kg or above) and adolescents with paroxysmal nocturnal haemoglobinuria (PNH), an ultra-rare and severe blood disorder characterised by the destruction of red blood cells that